D.E. Shaw & Co
PSTX

D.E. Shaw & Co’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

D.E. Shaw & Co’s Portfolio PSTX Stock Details PSTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-27,173
Closed -$47.8K – 4556
2023
Q2 		$47.8K Sell
27,173
-58,456
-68% -$149K ﹤0.01% 3882
2023
Q1 		$264K Sell
85,629
-253,492
-75% -$1.52M ﹤0.01% 3797
2022
Q4 		$1.8M Buy
339,121
+143,237
+73% +$655K ﹤0.01% 3022
2022
Q3 		$691K Buy
+195,884
New +$648K ﹤0.01% 3841

Other funds holding PSTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

D.E. Shaw & Co's PSTX Position: Q3 2023 in Review

D.E. Shaw & Co sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q3 2023, closing a stake of 27,173 shares — an estimated $47.8K sold.

D.E. Shaw & Co first reported a position in PSTX in Q3 2022 and held it in 4 quarters. The position peaked at $1.8M in Q4 2022. 86 funds tracked by Wall St. Rank hold PSTX as of Q3 2023.

  • D.E. Shaw & Co reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • D.E. Shaw & Co sold 27,173 Poseida Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $47.8K.
  • D.E. Shaw & Co first reported a position in Poseida Therapeutics, Inc. Common Stock in Q3 2022 and held it in 4 quarters.
  • D.E. Shaw & Co's Poseida Therapeutics, Inc. Common Stock position peaked at $1.8M in Q4 2022.
  • 86 funds tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q3 2023.

Based on D.E. Shaw & Co's 13F filing for Q3 2023, filed 14 Nov 2023.